|
1
|
Kam TI, Gwon Y and Jung YK: Amyloid beta
receptors responsible for neurotoxicity and cellular defects in
Alzheimer's disease. Cell Mol Life Sci. 71:4803–4813. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yoon PS, Ooi CH and How CH: Approach to
the forgetful patient. Singapore Med J. 59:121–125. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zheng Z, Wang J, Yi L, Yu H, Kong L, Cui
W, Chen H and Wang C: Correlation between behavioural and
psychological symptoms of Alzheimer type dementia and plasma
homocysteine concentration. BioMed Res Int. 2014:3834942014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Haibo X, Shifu X, Pin NT, Chao C, Guorong
M, Xuejue L, Shiming B, Wenli F, Jun L, Mingyuan Z, et al:
Prevalence and severity of behavioral and psychological symptoms of
dementia (BPSD) in community dwelling Chinese: Findings from the
Shanghai three districts study. Aging Ment Health. 17:748–752.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Song JA and Oh Y: The association between
the burden on formal caregivers and behavioral and psychological
symptoms of dementia (BPSD) in Korean elderly in nursing homes.
Arch Psychiatr Nurs. 29:346–354. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Savaskan E, Bopp-Kistler I, Buerge M,
Fischlin R, Georgescu D, Giardini U, Hatzinger M, Hemmeter U,
Justiniano I, et al: Recommendations for diagnosis and therapy of
behavioral and psychological symptoms in dementia (BPSD). Praxis
(Bern 1994). 103:135–148. 2014.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Savaskan E: Behavioral and psychological
symptoms of dementia (BPSD): How to proceed. Ther Umsch.
72:255–260. 2015.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Farlow MR, Graham SM and Alva G: Memantine
for the treatment of Alzheimer's disease tolerability and safety
data from clinical trial. Drug Saf. 31:1577–1585. 2008. View Article : Google Scholar
|
|
9
|
Maidment ID, Fox CG, Boustani M, Rodriguez
J, Brown RC and Katona CL: Efficacy of memantine on behavioral and
psychological symptoms related to dementia: A systematic
meta-analysis. Ann Pharmacother. 42:32–38. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rocca P, Marino F, Montemagni C, Perrone D
and Bogetto F: Risperidone, olanzapine and quetiapine in the
treatment of behavioral and psychological symptoms in patients with
Alzheimer's disease: Preliminary findings from a naturalistic,
retrospective study. Psychiatry Clin Neurosci. 61:622–629. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
De Deyn PP, Eriksson H and Svensson H:
Study of 115 investigators: Tolerability of extended-release
quetiapine fumarate compared with immediate-release quetiapine
fumarate in older patients with Alzheimer's disease with symptoms
of psychosis and/or agitation: A randomised, double-blind,
parallel-group study. Int J Geriatr Psychiatry. 27:296–304. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McNeal KM, Meyer RP, Lukacs K, Senseney A
and Mintzer J: Using risperidone for Alzheimer's
dementia-associated psychosis. Expert Opin Pharmacother.
9:2537–2543. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Katz I, de Deyn PP, Mintzer J, Greenspan
A, Zhu Y and Brodaty H: The efficacy and safety of risperidone in
the treatment of psychosis of Alzheimer's disease and mixed
dementia: A meta-analysis of 4 placebo-controlled clinical trials.
Int J Geriatr Psychiatry. 22:475–484. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rabinowitz J, Katz I, De Deyn PP,
Greenspan A and Brodaty H: Treating behavioral and psychological
symptoms in patients with psychosis of Alzheimer's disease using
risperidone. Int Psychogeriatr. 19:227–240. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Forloni G and Balducci C: Alzheimer's
disease, oligomers, and inflammation. J Alzheimers Dis.
62:1261–1276. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morgan BP: Complement in the pathogenesis
of Alzheimer's disease. Semin Immunopathol. 40:113–124. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Paleacu D, Barak Y, Mirecky I and Mazeh D:
Quetiapine treatment for behavioural and psychological symptoms of
dementia in Alzheimer's disease patients: A 6-week, double-blind,
placebo-controlled study. Int J Geriatr Psychiatry. 23:393–400.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M,
Chen CP, Francis PT, Lasheras B and Ramirez MJ:
Cholinergic-serotonergic imbalance contributes to cognitive and
behavioral symptoms in Alzheimer's disease. Neuropsychologia.
43:442–449. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lai MK, Tsang SW, Francis PT, Esiri MM,
Keene J, Hope T and Chen CP: Reduced serotonin 5-HT1A receptor
binding in the temporal cortex correlates with aggressive behavior
in Alzheimer disease. Brain Res. 974:82–87. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lam LC, Tang NL, Ma SL, Zhang W and Chiu
HF: 5-HT2A T102C receptor polymorphism and neuropsychiatric
symptoms in Alzheimer's disease. Int J Geriatr Psychiatry.
19:523–526. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Farina N, Morrell L and Banerjee S: What
is the therapeutic value of antidepressants in dementia? A
narrative review. Int J Geriatr Psychiatry. 32:32–49. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Porsteinsson AP, Drye LT, Pollock BG,
Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer
JE, Munro CA, et al: CitAD Research Group: Effect of citalopram on
agitation in Alzheimer disease: The CitAD randomized clinical
trial. JAMA. 311:682–691. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Porsteinsson AP, Keltz MA and Smith JS:
Role of citalopram in the treatment of agitation in Alzheimer's
disease. Neurodegener Dis Manag. 4:345–349. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Porsteinsson AP, Smith JS, Keltz MA and
Antonsdottir IM: Can antidepressant medication relieve agitation in
Alzheimer's disease? Expert Rev Neurother. 14:969–971. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Underwood BR and Fox C: Citalopram
decreases agitation in the context of Alzheimer's disease, but at
doses higher than those commonly prescribed and at the expense of
side effects. Evid Based Med. 19:1812014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cummings JL, Mega M, Gray K,
Rosenberg-Thompson S, Carusi DA and Gornbein J: The
Neuropsychiatric Inventory: Comprehensive assessment of
psychopathology in dementia. Neurology. 44:2308–2314. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Otero MC and Levenson RW: Lower visual
avoidance in dementia patients is associated with greater
psychological distress in caregivers. Dement Geriatr Cogn Disord.
43:247–258. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Drye LT, Ismail Z, Porsteinsson AP,
Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins
PV, Munro CA, et al: CitAD Research Group: Citalopram for agitation
in Alzheimer's disease: Design and methods. Alzheimers Dement.
8:121–130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Weintraub D, Drye LT, Porsteinsson AP,
Rosenberg PB, Pollock BG, Devanand DP, Frangakis C, Ismail Z,
Marano C, Meinert CL, et al: CitAD Research Group: Time to response
to citalopram treatment for agitation in Alzheimer Disease. Am J
Geriatr Psychiatry. 23:1127–1133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hellen F, Supprian T, Salamon T and
Lange-Asschenfeldt C: Resumption of food and fluid intake in
Alzheimer's disease with severe apathy following intravenous
citalopram. Psychiatry Clin Neurosci. 66:822012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cirrito JR, Disabato BM, Restivo JL,
Verges DK, Goebel WD, Sathyan A, Hayreh D, D'Angelo G, Benzinger T,
Yoon H, et al: Serotonin signaling is associated with lower
amyloid-β levels and plaques in transgenic mice and humans. Proc
Natl Acad Sci USA. 108:14968–14973. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ren QG, Gong WG, Wang YJ, Zhou QD and
Zhang ZJ: Citalopram attenuates tau hyperphosphorylation and
spatial memory deficit induced by social isolation rearing in
middle-aged rats. J Mol Neurosci. 56:145–153. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Erickson MA and Banks WA: Neuroimmune axes
of the blood-brain barriers and blood-brain interfaces: Bases for
physiological regulation, disease states, and pharmacological
interventions. Pharmacol Rev. 70:278–314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pimenova AA, Thathiah A, De Strooper B and
Tesseur I: Regulation of amyloid precursor protein processing by
serotonin signaling. PLoS One. 9:e870142014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Deltheil T, Guiard BP, Cerdan J, David DJ,
Tanaka KF, Repérant C, Guilloux JP, Coudoré F, Hen R and Gardier
AM: Behavioral and serotonergic consequences of decreasing or
increasing hippocampus brain-derived neurotrophic factor protein
levels in mice. Neuropharmacology. 55:1006–1014. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Klyubin I, Cullen WK, Hu NW and Rowan MJ:
Alzheimer's disease Aβ assemblies mediating rapid disruption of
synaptic plasticity and memory. Mol Brain. 5:252012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wolkowitz OM, Wolf J, Shelly W, Rosser R,
Burke HM, Lerner GK, Reus VI, Nelson JC, Epel ES and Mellon SH:
Serum BDNF levels before treatment predict SSRI response in
depression. Prog Neuropsychopharmacol Biol Psychiatry.
35:1623–1630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
van der Meij A, Comijs HC, Dols A, Janzing
JG and Oude Voshaar RC: BDNF in late-life depression: Effect of
SSRI usage and interaction with childhood abuse.
Psychoneuroendocrinology. 43:81–89. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ren QG, Wang YJ, Gong WG, Zhou QD, Xu L
and Zhang ZJ: Escitalopram ameliorates forskolin-induced tau
hyperphosphorylation in HEK239/tau441 cells. J Mol Neurosci.
56:500–508. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang YJ, Ren QG, Gong WG, Wu D, Tang X, Li
XL, Wu FF, Bai F, Xu L and Zhang ZJ: Escitalopram attenuates
β-amyloid-induced tau hyperphosphorylation in primary hippocampal
neurons through the 5-HT1A receptor mediated Akt/GSK-3β pathway.
Oncotarget. 7:13328–13339. 2016.PubMed/NCBI
|
|
41
|
Su F, Yi H, Xu L and Zhang Z: Fluoxetine
and S-citalopram inhibit M1 activation and promote M2 activation of
microglia in vitro. Neuroscience. 294:60–68. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wenzel-Seifert K, Wittmann M and Haen E:
QTc prolongation by psychotropic drugs and the risk of torsade de
pointes. Dtsch Arztebl Int. 108:687–693. 2011.PubMed/NCBI
|
|
43
|
Vieweg WV, Hasnain M, Howland RH, Hettema
JM, Kogut C, Wood MA and Pandurangi AK: Citalopram, QTc interval
prolongation, and torsade de pointes. How should we apply the
recent FDA ruling? Am J Med. 125:859–868. 2012.PubMed/NCBI
|
